Baqsimi

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Ladda ner Bipacksedel (PIL)
30-05-2024
Ladda ner Produktens egenskaper (SPC)
30-05-2024

Aktiva substanser:

Glucagon

Tillgänglig från:

Eli Lilly Nederland B.V.

ATC-kod:

H04AA01

INN (International namn):

glucagon

Terapeutisk grupp:

Pancreatic hormones, Glycogenolytic hormones

Terapiområde:

Diabetes Mellitus

Terapeutiska indikationer:

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Produktsammanfattning:

Revision: 1

Bemyndigande status:

Authorised

Tillstånd datum:

2019-12-16

Bipacksedel

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BAQSIMI 3 MG NASAL POWDER IN SINGLE-DOSE CONTAINER
glucagon
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Baqsimi is and what it is used for
2.
What you need to know before you are given Baqsimi
3.
How Baqsimi is given
4.
Possible side effects
5.
How to store Baqsimi
6.
Contents of the pack and other information
1.
WHAT BAQSIMI IS AND WHAT IT IS USED FOR
Baqsimi contains the active substance glucagon, which belongs to a
group of medicines called
glycogenolytic hormones. It is used to treat severe hypoglycaemia
(very low blood sugar) in people
with diabetes. It is for use in adults, adolescents, and children aged
4 years or older.
Glucagon is a natural hormone produced by the pancreas. It works in
the opposite way to insulin and
raises blood sugar. It does this by converting stored sugar in the
liver called glycogen to glucose (a
form of sugar that the body uses for energy). The glucose then enters
the bloodstream and raises the
blood sugar level, so reducing the effects of hypoglycaemia.
You should always carry Baqsimi with you and tell your friends and
family that you are carrying it.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN BAQSIMI
_ _
IMPORTANT INFORMATION
If you are at risk of severe hypoglycaemia you should always have
Baqsimi readily available:
-
show your family members, friends, or people you work with where you
keep this medicine and
explain when and how to use it. Delay in treatment may be harmful
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Baqsimi 3 mg nasal powder in single-dose container
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single-dose container delivers nasal powder with 3 mg of
glucagon.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal powder in single-dose container (nasal powder).
White to practically white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Baqsimi is indicated for the treatment of severe hypoglycaemia in
adults, adolescents, and children
aged 4 years and over with diabetes mellitus.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults, adolescents and children aged 4 years and over _
The recommended dose is 3 mg glucagon administered into one nostril.
_Elderly _(≥ 65 years)_ _
No dose adjustment is required based on age.
Efficacy and safety data are very limited in patients aged 65 years
and absent in patients aged 75 and
above.
_ _
_Renal and hepatic impairment _
No dose adjustment is required based on renal and hepatic function.
_ _
_Paediatric population 0 - < 4 years _
The safety and efficacy of Baqsimi in infants and children aged 0 to <
4 years have not yet been
established. No data are available.
Method of administration
Nasal use only. Glucagon nasal powder is given in a single nostril.
Glucagon is passively absorbed
through the nasal mucosa. It is not necessary to inhale or breathe
deeply after dosing.
INSTRUCTIONS FOR ADMINISTERING GLUCAGON NASAL POWDER
1.
Remove the shrink wrap by pulling on the red stripe.
2.
Remove the single-dose container from the tube. Do not press the
plunger until ready to give the
dose.
3.
Hold the single-dose container between fingers and thumb. Do not test
before use as it contains
3
only one dose of glucagon and cannot be reused.
4.
Insert the tip of the single-dose container gently in one of the
nostrils until finger(s) touch the
outside of the nose.
5.
Push the plunger all the way in. The dose is complete when the green
line is no longer showin
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 30-05-2024
Produktens egenskaper Produktens egenskaper bulgariska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 21-09-2023
Bipacksedel Bipacksedel spanska 30-05-2024
Produktens egenskaper Produktens egenskaper spanska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 21-09-2023
Bipacksedel Bipacksedel tjeckiska 30-05-2024
Produktens egenskaper Produktens egenskaper tjeckiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 21-09-2023
Bipacksedel Bipacksedel danska 30-05-2024
Produktens egenskaper Produktens egenskaper danska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 21-09-2023
Bipacksedel Bipacksedel tyska 30-05-2024
Produktens egenskaper Produktens egenskaper tyska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 21-09-2023
Bipacksedel Bipacksedel estniska 30-05-2024
Produktens egenskaper Produktens egenskaper estniska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 21-09-2023
Bipacksedel Bipacksedel grekiska 30-05-2024
Produktens egenskaper Produktens egenskaper grekiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 21-09-2023
Bipacksedel Bipacksedel franska 30-05-2024
Produktens egenskaper Produktens egenskaper franska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 21-09-2023
Bipacksedel Bipacksedel italienska 30-05-2024
Produktens egenskaper Produktens egenskaper italienska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 21-09-2023
Bipacksedel Bipacksedel lettiska 30-05-2024
Produktens egenskaper Produktens egenskaper lettiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 21-09-2023
Bipacksedel Bipacksedel litauiska 30-05-2024
Produktens egenskaper Produktens egenskaper litauiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 21-09-2023
Bipacksedel Bipacksedel ungerska 30-05-2024
Produktens egenskaper Produktens egenskaper ungerska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 21-09-2023
Bipacksedel Bipacksedel maltesiska 30-05-2024
Produktens egenskaper Produktens egenskaper maltesiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 21-09-2023
Bipacksedel Bipacksedel nederländska 30-05-2024
Produktens egenskaper Produktens egenskaper nederländska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 21-09-2023
Bipacksedel Bipacksedel polska 30-05-2024
Produktens egenskaper Produktens egenskaper polska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 21-09-2023
Bipacksedel Bipacksedel portugisiska 30-05-2024
Produktens egenskaper Produktens egenskaper portugisiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 21-09-2023
Bipacksedel Bipacksedel rumänska 30-05-2024
Produktens egenskaper Produktens egenskaper rumänska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 21-09-2023
Bipacksedel Bipacksedel slovakiska 30-05-2024
Produktens egenskaper Produktens egenskaper slovakiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 21-09-2023
Bipacksedel Bipacksedel slovenska 30-05-2024
Produktens egenskaper Produktens egenskaper slovenska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 21-09-2023
Bipacksedel Bipacksedel finska 30-05-2024
Produktens egenskaper Produktens egenskaper finska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 21-09-2023
Bipacksedel Bipacksedel svenska 30-05-2024
Produktens egenskaper Produktens egenskaper svenska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 21-09-2023
Bipacksedel Bipacksedel norska 30-05-2024
Produktens egenskaper Produktens egenskaper norska 30-05-2024
Bipacksedel Bipacksedel isländska 30-05-2024
Produktens egenskaper Produktens egenskaper isländska 30-05-2024
Bipacksedel Bipacksedel kroatiska 30-05-2024
Produktens egenskaper Produktens egenskaper kroatiska 30-05-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 21-09-2023

Sök varningar relaterade till denna produkt

Visa dokumenthistorik